Dale Broadrick Buys 10,000 Shares of BioRestorative Therapies, Inc. (NASDAQ:BRTX) Stock

BioRestorative Therapies, Inc. (NASDAQ:BRTX) major shareholder Dale Broadrick acquired 10,000 shares of BioRestorative Therapies stock in a transaction on Thursday, September 14th. The stock was purchased at an average price of $1.54 per share, with a total value of $15,400.00. Following the purchase, the insider now owns 317,573 shares of the company’s stock, valued at approximately $489,062.42. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Dale Broadrick also recently made the following trade(s):

• On Thursday, September 7th, Dale Broadrick acquired 1,000 shares of BioRestorative Therapies stock. The stock was purchased at an average price of $1.81 per share, with a total value of $1,810.00.
• On Friday, July 28th, Dale Broadrick acquired 500 shares of BioRestorative Therapies stock. The stock was purchased at an average price of $2.89 per share, with a total value of $1,445.00.

BioRestorative Therapies Stock Performance

Shares of BioRestorative Therapies stock traded up $0.27 during trading hours on Monday, hitting $1.94. 343,400 shares of the company were exchanged, compared to its average volume of 243,439. BioRestorative Therapies, Inc. has a 1 year low of $1.41 and a 1 year high of $7.13.

BioRestorative Therapies (NASDAQ:BRTX) last released its quarterly earnings data on Friday, August 11th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.56) by $0.79. The firm had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.03 million. BioRestorative Therapies had a negative return on equity of 120.47% and a negative net margin of 13,728.83%. As a group, research analysts anticipate that BioRestorative Therapies, Inc. will post -3.52 EPS for the current fiscal year.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.